Advisors Asset Management Inc. Has $5.41 Million Position in Cencora, Inc. $COR

Advisors Asset Management Inc. boosted its holdings in Cencora, Inc. (NYSE:COR) by 40.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,302 shares of the company’s stock after acquiring an additional 4,973 shares during the period. Advisors Asset Management Inc.’s holdings in Cencora were worth $5,407,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. CWM LLC grew its stake in Cencora by 15.4% in the 2nd quarter. CWM LLC now owns 11,792 shares of the company’s stock valued at $3,536,000 after buying an additional 1,575 shares during the last quarter. MGO One Seven LLC boosted its holdings in shares of Cencora by 30.6% during the second quarter. MGO One Seven LLC now owns 3,298 shares of the company’s stock worth $989,000 after acquiring an additional 772 shares during the period. Sequoia Financial Advisors LLC grew its position in shares of Cencora by 3.1% in the second quarter. Sequoia Financial Advisors LLC now owns 9,683 shares of the company’s stock valued at $2,903,000 after purchasing an additional 291 shares during the last quarter. RFG Advisory LLC acquired a new position in shares of Cencora in the second quarter valued at approximately $604,000. Finally, Sagespring Wealth Partners LLC increased its stake in shares of Cencora by 7.2% during the second quarter. Sagespring Wealth Partners LLC now owns 2,046 shares of the company’s stock worth $614,000 after purchasing an additional 138 shares during the period. 97.52% of the stock is owned by institutional investors.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the transaction, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at $23,669,713.98. This trade represents a 7.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 20,316 shares of company stock worth $7,151,265 over the last three months. Company insiders own 0.38% of the company’s stock.

Wall Street Analysts Forecast Growth

COR has been the subject of several recent research reports. Robert W. Baird set a $415.00 price target on Cencora in a research note on Tuesday, January 13th. TD Cowen boosted their target price on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Weiss Ratings upgraded shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. UBS Group lifted their price objective on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Finally, Bank of America decreased their target price on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $396.92.

Cencora Trading Down 3.8%

Shares of COR stock opened at $351.91 on Friday. The stock’s fifty day simple moving average is $347.08 and its 200 day simple moving average is $327.83. Cencora, Inc. has a twelve month low of $237.71 and a twelve month high of $377.54. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. The firm has a market capitalization of $68.27 billion, a P/E ratio of 42.30, a P/E/G ratio of 1.69 and a beta of 0.68.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business had revenue of $85.93 billion during the quarter, compared to analyst estimates of $86.12 billion. During the same quarter last year, the business earned $3.73 EPS. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. As a group, sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is currently 28.85%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.